Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LTI-03 · 2 trials · 2 indications
Incidence of TEAEs by dose
| Arm | Type | Description |
|---|---|---|
| (1) 2.5 mg LTI-03 capsule BID | EXPERIMENTAL | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| (2) 2.5 mg LTI-03 capsules BID | EXPERIMENTAL | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| (1) Placebo capsule BID | PLACEBO_COMPARATOR | Lactose powder |
| (2) Placebo capsules BID | PLACEBO_COMPARATOR | Lactose powder |
| 2.5 mg LTI-03 BID | EXPERIMENTAL | 2.5 mg LTI-03 BID x 14 days |
| 5 mg LTI-03 BID | EXPERIMENTAL | 5 mg LTI-03 BID x 14 days |
| Placebo | PLACEBO_COMPARATOR | Matching placebo BID x 14 days |
| Name | Type | Description |
|---|---|---|
| LTI-03 | DRUG | Caveolin-1-Scaffolding-Protein-Derived Peptide |
| Dry Powder Inhaler | DEVICE | Plastiape Monodose RS01 Model 7 |
| Placebo | DRUG | Lactose powder |
Inclusion Criteria: 1. Male or female age 40 years or older. 2. Willing and able to provide written informed consent. 3. Diagnosis of IPF within 5 years of Screening as confirmed by a centrally read HRCT of the chest as defined by the ATS/ERS/JRS/ALAT guideline. HRCT lung fibrosis by central read d...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Treprostinil |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| PureTech Health PLC Sponsored ADR | PRTC | 2 | PHASE3 | Deupirfenidone, Pirfenidone |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 Dose A, PIPE-791 Dose B |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | HEC585, Pirfenidone |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01 |
LTI-03 is an investigational small molecule being developed for Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease. It is being studied in patients with IPF, including newly diagnosed patients. The drug is not yet approved and is currently in clinical development, with early-phase trials evaluating its safety and efficacy in this condition.
LTI-03 is a small molecule therapeutic being developed for Idiopathic Pulmonary Fibrosis. Its specific molecular target has not been disclosed in available information. The drug is being studied for its potential to treat IPF, a condition characterized by lung scarring and declining respiratory function.
LTI-03 is being developed by Rein Therapeutics, Inc., a biopharmaceutical company traded under the ticker symbol RNTX. The company is conducting clinical trials to evaluate the drug's safety and effectiveness in patients with Idiopathic Pulmonary Fibrosis.
LTI-03 is currently in Phase 2 clinical development for Idiopathic Pulmonary Fibrosis. A Phase 1 study has been completed, and a Phase 2 trial is actively recruiting participants. The drug has received Orphan Drug and Fast Track designations from the FDA, but it is not yet approved.
LTI-03 has been studied in two clinical trials. NCT05954988 was a completed Phase 1 study in newly diagnosed IPF patients. NCT06968845 is an ongoing Phase 2 study in IPF patients, currently recruiting in the United States, Australia, Germany, Poland, and the United Kingdom.
LTI-03 is not known to have any alternative names. It is a distinct investigational small molecule being developed by Rein Therapeutics for Idiopathic Pulmonary Fibrosis. No other names for this drug have been reported in clinical trial registrations.